IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.59+2.14 (+5.57%)
Close on Nov 18, 2026Market cap $41.28MP/E –Yield –
IRulya Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
IRulya Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$127.16M. For fiscal 2025 it was -$58.07M. The highest annual figure on record is -$12.12M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.07M | – |
| FY2024 | Dec 31, 2024 | -$57.29M | – |
| FY2023 | Dec 31, 2023 | -$34.62M | – |
| FY2022 | Dec 31, 2022 | -$52.02M | – |
| FY2021 | Dec 31, 2021 | -$90.32M | – |
| FY2020 | Dec 31, 2020 | -$78.89M | – |
| FY2019 | Dec 31, 2019 | -$39.17M | – |
| FY2018 | Dec 31, 2018 | -$12.12M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$79.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.43M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.85M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.95M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.08M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.84M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.87M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.64M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.76M | – |
See a number that looks wrong?